KMT2B
Summary: This gene encodes a protein which contains multiple domains including a CXXC zinc finger, three PHD zinc fingers, two FY-rich domains, and a SET (suppressor of variegation, enhancer of zeste, and trithorax) domain. The SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. This gene is ubiquitously expressed in adult tissues. It is also amplified in solid tumor cell lines, and may be involved in human cancer. Two alternatively spliced transcript variants encoding distinct isoforms have been reported for this gene, however, the full length nature of the shorter transcript is not known. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| lysine methyltransferase 2B | MIM:606834 | Ensembl:ENSG00000272333 | HGNC:HGNC:15840 | PA166123699 | 19q13.12 |
GO terms in KMT2B
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | IDA | GO:0005634 | nucleus |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0035097 | histone methyltransferase complex |
| BP | IEA | GO:0001541 | ovarian follicle development |
| BP | IEA | GO:0006351 | transcription, DNA-templated |
| BP | IEA | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0007613 | memory |
| BP | IEA | GO:0009994 | oocyte differentiation |
| BP | IEA | GO:0016458 | gene silencing |
| BP | IEA | GO:0030728 | ovulation |
| BP | TAS | GO:0045652 | regulation of megakaryocyte differentiation |
| BP | NAS | GO:0048096 | chromatin-mediated maintenance of transcription |
| BP | IMP | GO:0051568 | histone H3-K4 methylation |
| BP | IEA | GO:0051569 | regulation of histone H3-K4 methylation |
| BP | IEA | GO:0080182 | histone H3-K4 trimethylation |
| MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | IEA | GO:0003677 | DNA binding |
| MF | NAS | GO:0003700 | DNA-binding transcription factor activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0008270 | zinc ion binding |
| MF | TAS | GO:0018024 | histone-lysine N-methyltransferase activity |
| MF | IDA | GO:0042800 | histone methyltransferase activity (H3-K4 specific) |
Gene expression in normal tissue: KMT2B
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in KMT2B
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| kegg | hsa00310 | Lysine degradation - Homo sapiens (human) |
| wikipathways | WP2369 | Histone Modifications |
| reactome | R-HSA-212436 | Generic Transcription Pathway |
| reactome | R-HSA-3214841 | PKMTs methylate histone lysines |
| reactome | R-HSA-3247509 | Chromatin modifying enzymes |
| reactome | R-HSA-4839726 | Chromatin organization |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-8878171 | Transcriptional regulation by RUNX1 |
| reactome | R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD593 | CX-5461 | 4 |
| iGMDRD458 | GSK-319347A | 1 |
| iGMDRD585 | MPS1-IN-1 | 1 |
| iGMDRD431 | NU-7441 | 1 |
| iGMDRD283 | Bosutinib | 2 |
| iGMDRD135 | Lenalidomide | 1 |
| iGMDRD749 | ZINC6718453 | 2 |
| iGMDRD443 | Linifanib | 1 |
| iGMDRD12 | Bicalutamide | 3 |
| iGMDRD668 | GSK 525762A | 1 |
| iGMDRD687 | I-BET151 | 1 |
| iGMDRD639 | YK 4-279 | 1 |
| iGMDRD326 | Belinostat (PXD101) | 1 |
| iGMDRD667 | BIX02189 | 2 |
| iGMDRD655 | SCHEMBL618594 | 3 |
| iGMDRD215 | CCT007093 | 1 |
| iGMDRD660 | GSK-1070916 | 2 |
| iGMDRD289 | Parthenolide | 1 |
| iGMDRD293 | Bleomycin | 2 |
| iGMDRD672 | Alectinib | 1 |
| iGMDRD103 | SN-38 | 1 |
| iGMDRD366 | PI-103 | 1 |
| iGMDRD442 | BMS-509744 | 1 |
| iGMDRD50 | Cytarabine | 2 |
| iGMDRD532 | Olaparib | 1 |
| iGMDRD324 | CI-1040 | 1 |
| iGMDRD370 | TPCA-1 | 2 |
| iGMDRD475 | BX 912 | 1 |
| iGMDRD541 | SNX-2112 (PF-04928473) | 1 |
| iGMDRD478 | ABT-888 | 1 |
| iGMDRD388 | YM201636 | 1 |
| iGMDRD261 | OSI-027 | 2 |
| iGMDRD758 | JW-7-24-1 | 1 |
| iGMDRD573 | GSK-1904529A | 1 |
| iGMDRD539 | CUDC-101 | 1 |
| iGMDRD33 | Entinostat | 1 |
| iGMDRD320 | PIK-93 | 2 |
| iGMDRD916 | Genentech Cpd 10 | 1 |
| iGMDRD509 | NVP-BHG712 | 2 |
| iGMDRD669 | PDK1 inhibitor | 2 |
| iGMDRD598 | QS-11 | 1 |
| iGMDRD131 | Erlotinib | 1 |
| iGMDRD432 | AT-7519 | 1 |
| iGMDRD127 | Seliciclib | 1 |
| iGMDRD453 | GW2580 | 1 |
| iGMDRD312 | Pelitinib | 2 |
| iGMDRD678 | Tubastatin A | 2 |
| iGMDRD63 | Camptothecin | 1 |
| iGMDRD54 | Phenformin | 2 |
| iGMDRD659 | Avagacestat (BMS-708163) | 1 |
| iGMDRD282 | GNF-2 | 1 |
| iGMDRD112 | Methotrexate | 1 |
| iGMDRD776 | QL-XI-92 | 1 |
| iGMDRD696 | NG25 | 1 |
| iGMDRD519 | GDC-0941 | 1 |
| iGMDRD733 | SGC0946 | 1 |
| iGMDRD389 | SB525334 | 2 |
| iGMDRD172 | T091317 | 2 |
| iGMDRD558 | CAY10603 | 1 |
| iGMDRD1016 | THZ-2-49 | 1 |
| iGMDRD412 | VX-702 | 1 |
| iGMDRD556 | Quizartinib | 1 |
| iGMDRD646 | PHA-793887 | 1 |
| iGMDRD695 | FR-180204 | 1 |
| iGMDRD755 | XMD13-2 | 2 |
| iGMDRD3 | PD-173074 | 1 |
| iGMDRD1015 | THZ-2-102-1 | 2 |
| iGMDRD125 | BIRB-796 | 1 |
| iGMDRD347 | Y-39983 | 2 |
| iGMDRD360 | SB-505124 | 1 |
| iGMDRD463 | ZSTK 474 | 1 |
| iGMDRD262 | KU-55933 | 1 |
| iGMDRD784 | QL-X-138 | 2 |
| iGMDRD292 | NSC87877 | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in KMT2B
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.